DnB Asset Management
SNDX icon

DnB Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

DnB Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$492K Buy
22,514
+5,862
+35% +$122K ﹤0.01% 802
2026
Q1 		$389K Sell
16,652
-13,108
-44% -$285K ﹤0.01% 859
2025
Q4 		$625K Buy
29,760
+6,466
+28% +$113K ﹤0.01% 672
2025
Q3 		$358K Sell
23,294
-6,068
-21% -$79.4K ﹤0.01% 687
2025
Q2 		$275K Buy
29,362
+6,984
+31% +$76.9K ﹤0.01% 678
2025
Q1 		$275K Sell
22,378
-565
-2% -$7.97K ﹤0.01% 694
2024
Q4 		$303K Buy
22,943
+5,581
+32% +$95.5K ﹤0.01% 688
2024
Q3 		$334K Buy
17,362
+4,190
+32% +$86.6K ﹤0.01% 676
2024
Q2 		$270K Buy
13,172
+3,804
+41% +$79.6K ﹤0.01% 679
2024
Q1 		$223K Buy
+9,368
New +$209K ﹤0.01% 693

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

DnB Asset Management's SNDX Position: Q2 2026 in Review

DnB Asset Management increased its Syndax Pharmaceuticals (SNDX) stake by 35% in Q2 2026, buying an estimated $122K and bringing the position to 22,514 shares worth $492K. The position accounts for ﹤0.01% of the portfolio, ranked #802.

DnB Asset Management first reported a position in SNDX in Q1 2024 and has held it in 10 quarters since. The position peaked at $625K in Q4 2025. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • DnB Asset Management held 22,514 shares of Syndax Pharmaceuticals worth $492K as of Q2 2026.
  • DnB Asset Management bought 5,862 Syndax Pharmaceuticals shares in Q2 2026, an estimated $122K.
  • Syndax Pharmaceuticals made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #802 holding.
  • DnB Asset Management first reported a position in Syndax Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • DnB Asset Management's Syndax Pharmaceuticals position peaked at $625K in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.